Monday, November 4, 2024
Facebook Linkedin Twitter
HomeTagsJanssen Pharmaceutical

Janssen Pharmaceutical

Biotechnology

Janssen Presents Efficacy and Subgroup Analyses from MAIA Study Showing Long-Term Results

PR Newswire -
The Janssen Pharmaceutical Companies of Johnson & Johnson announced new analyses from the Phase 3 MAIA study of DARZALEX in combination with lenalidomide and...
Biotechnology

FDA Approves Two New Indications for XARELTO (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients

PR Newswire -
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO...
Healthcare

New Data from MajesTEC-1 Study Show Continued Deep and Durable Responses of Teclistamab (BCMAxCD3 Bispecific Antibody) in Treatment of Heavily Pretreated Patients with Multiple...

PR Newswire -
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the first presentation of Phase 2 data and updated Phase 1 data from the MajesTEC-1...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics

Load more
ReadMagazine © | All rights reserved |Contact Us | Privacy Policy| Become A Guest Writer | Advertise with Us